Pilot Study Based on Technology Solutions for Hypertension Care
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to understand whether the adoption of digital solutions by healthcare professionals and patients improves the management of patients with high blood pressure.
The main questions it aims to answer are:
-
are these digital solutions feasible and well accepted by patients?
-
can these solutions, compared to standard care, allow a better hypertension control in patients with high blood pressure?
Participants randomised to one of the two intervention arms will be asked to adopt the digital solutions that include a smartphone app and 2 devices for blood pressure and body weight measurement that will be connected to the app.
Researchers will compare patients randomised in the two intervention groups with patients randomised to standard care (control group)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The study falls within the scope of the HSMonitor project, a pre-commercial tender for the development of telematics solutions aimed at optimising patient health status and disease management. Specifically, the aim of this study is to test whether the adoption of HSMonitor solutions by healthcare professionals and patients improves the management of patients with high blood pressure.
This will be a randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions or to standard care.
The present pilot study is planned to be carried out within the framework of the EU project HSMonitor - Pre-commercial Procurement of innovative ICT-enabled monitoring to improve health status and optimize hypertension care (Grant Agreement Nr. 856698).
The two solutions are referred to as:
-
Solution 1 - HSmartBPM (developed by a supplier consortium led by GNOMON)
-
Solution 2 - HyperHealth (developed by a supplier consortium led by TECH4CARE)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Solution 1 - HSmartBPM (developed by a supplier consortium led by GNOMON) Solutions consist of devices (e.g., blood pressure monitors, body composition scales) working together in an ecosystem enabled by a user-facing service and associated interfaces. Users are invited to a dedicated training session at the pilot site to officially become enrolled and begin using the solution for an extended period of time. During that time, users are instructed to use the solutions based on recommendations by their treating physicians (e.g., regular measurement of blood pressure using the solution, or scheduling of regular visits via the solution interface). Questionnaires are administered via the solution's interface at the beginning and end of the trial duration. At the end of the trial, the user is asked to return the devices to the pilot site. |
Device: digital solution
randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
|
| Other: Solution 2 - HyperHealth (developed by a supplier consortium led by TECH4CARE) Solutions consist of devices (e.g., blood pressure monitors, body composition scales) working together in an ecosystem enabled by a user-facing service and associated interfaces. Users are invited to a dedicated training session at the pilot site to officially become enrolled and begin using the solution for an extended period of time. During that time, users are instructed to use the solutions based on recommendations by their treating physicians (e.g., regular measurement of blood pressure using the solution, or scheduling of regular visits via the solution interface). Questionnaires are administered via the solution's interface at the beginning and end of the trial duration. At the end of the trial, the user is asked to return the devices to the pilot site. |
Device: digital solution
randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
|
| Other: control the control group where they will be followed according to standard care |
Other: Standard Care
randomised controlled trial where patients with hypertension will be randomised r to standard care
|
Outcome Measures
Primary Outcome Measures
- Changes in blood pressure [2 and 6 months]
The changes in systolic and diastolic blood pressure
Secondary Outcome Measures
- The user satisfaction measured with VAS [2 and 6 months]
0-100 points VAS where 0 means not satisfied and 100 fully satisfied
Other Outcome Measures
- Quality of life measured with EQ-5D [2 and 6 months]
EQ-5D is a standardised measure of health-related quality of life
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with essential hypertension (>140/90 mmHg or normal BP with antihypertensive treatment)
-
Basic ICT knowledge and ability to access the internet at home and on mobile devices
-
aged 18+
-
ability to provide written informed consent, giving informed consent.
-
written informed consent
Exclusion Criteria:
-
inability to consent
-
chronic renal replacement therapy (haemodialysis, peritoneal dialysis or transplantation) or if, at baseline, there is a history of active malignancy within the last five years
-
pregnancy
-
illiterate
-
younger than 18 years
-
being a prisoner
-
being institutionalized
-
the patient is mentally or psychiatrically ill
-
the patient has barriers to understand the implications of participation to the study
-
the patient is critically ill or dying
-
the patient is extremely poor
-
the patient has a learning disability
-
the patient is sedated or unconscious
-
the patient is a refugee with no permanent permission to stay
-
the patient does not have a good command of the language
-
the patient has problems in cognitive, juridical, and deferential dimensions
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Istituto Auxologico Italiano IRCCS | Milan | Italy | 20149 |
Sponsors and Collaborators
- Istituto Auxologico Italiano
Investigators
- Principal Investigator: Gianfranco Parati, MD, Istituto Auxologico Italiano
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 09E801